$54.93
1.82 (-3.21%)
Last updated: Jul 15, 2026 04:28
Fundamentals Overview
Ionis Pharmaceuticals, Inc. is in the middle of its 52-week range with premium valuation, trending downward today.
Valuation premium
Risk (Beta)
0.37 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Pressures (Sell):
Analyst grade: D+ · 3M vs S&P 500: -36.3% · 3M vs Healthcare sector: -33.7%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: D+. Current institutional positions: Buy: 14, Hold: 1, Neutral: 1, Outperform: 6, Overweight: 8.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-86.08; current price is $54.93. That’s a -256.7% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 18.43 |
| P/S (TTM) | 8.58 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 4.1 |
| Quick Ratio (TTM) | 4.09 |
| Cash Ratio (TTM) | 0.24 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -30.87% |
| Gross margin (TTM) | 98.35% |
| Operating margin (TTM) | -33.35% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for IONS.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| RBC Capital | maintain | Outperform | Outperform | 2026-07-13 |
| Barclays | maintain | Overweight | Overweight | 2026-07-10 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-07-10 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-07-10 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-07-10 |
| Citigroup | maintain | Buy | Buy | 2026-07-10 |
| Jefferies | maintain | Buy | Buy | 2026-07-09 |
| Needham | maintain | Buy | Buy | 2026-07-09 |
| Goldman Sachs | maintain | Neutral | Neutral | 2026-06-25 |
| Leerink Partners | maintain | Outperform | Outperform | 2026-06-25 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-06-25 |
| Leerink Partners | maintain | Outperform | Outperform | 2026-06-17 |
| TD Cowen | maintain | Buy | Buy | 2026-06-15 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-06-01 |
| Barclays | maintain | Overweight | Overweight | 2026-04-30 |
| RBC Capital | maintain | Outperform | Outperform | 2026-04-30 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-04-30 |
| TD Cowen | maintain | Buy | Buy | 2026-04-23 |
| Morgan Stanley | maintain | Overweight | Overweight | 2026-04-21 |
| B of A Securities | maintain | Buy | Buy | 2026-04-09 |
| Barclays | maintain | Overweight | Overweight | 2026-03-26 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-25 |
| Needham | maintain | Buy | Buy | 2026-03-25 |
| Leerink Partners | maintain | Outperform | Outperform | 2026-03-03 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-02-27 |
| Stifel | maintain | Hold | Hold | 2026-02-26 |
| Needham | maintain | Buy | Buy | 2026-02-26 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-02-06 |
| Wells Fargo | maintain | Overweight | Overweight | 2026-01-05 |
| RBC Capital | maintain | Outperform | Outperform | 2025-12-17 |